新型经支气管射频消融系统治疗肺肿瘤的安全性与疗效:BRONC-RFII 多中心试验一年随访
BRONC-RFII 是一项在 16 个医疗中心开展的首个多中心大规模临床试验,纳入 126 例恶性肺肿瘤患者(130 个肿瘤),评估经支气管射频消融(RFA)联合自动盐水微灌注系统的技术性能、疗效与安全性。主要终点完全消融率在 12 个月随访时为 90.48%,纯磨玻璃结节(GGN)完全消融率优于实性结节(100% vs 82.14%,p=0.007),未报告器械缺陷。
要点
- 经支气管 RFA 联合自动盐水微灌注系统技术成功率达 99.35%,无器械缺陷报告。
- 12 个月完全消融率 90.48%,纯 GGN 与混合 GGN 优于实性结节。
- 主要并发症包括肺感染 11.11%、胸痛 10.32%、胸腔积液 8.73%、咯血 6.35%、气胸 3.97%。
核心结论
- 经支气管 RFA 联合自动盐水微灌注系统是治疗肺肿瘤可行、安全且有效的方法,尤其适用于 GGN 患者。
研究设计与样本
- 多中心、大规模临床试验,2021 年 1 月至 12 月在 16 个医疗中心纳入 126 例恶性肺肿瘤患者(130 个肿瘤),共行 153 次经支气管 RFA sessions。
主要发现
- 技术成功率为 99.35%,平均消融区大小为 32.47 mm。
- 12 个月随访时完全消融率为 90.48%,肺内无进展生存率为 88.89%。
- 12 个月完全消融率:实性结节 82.14%、纯 GGN 100%、混合 GGN 96.08%,p=0.007。
- 并发症发生率:气胸 3.97%、咯血 6.35%、胸腔积液 8.73%、肺感染 11.11%、胸痛 10.32%;随访期间 2 例死亡。
临床怎么用
- 对于恶性肺肿瘤,尤其是 GGN 患者,可考虑经支气管 RFA 联合自动盐水微灌注系统作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Radiofrequency ablation (RFA) is an emerging treatment of lung cancer, yet it is accompanied by certain safety concerns and operational limitations. This first multi-centre, large-scale clinical trial aimed to investigate the technical performance, efficacy and safety of an innovative transbronchial RFA system for lung tumours. METHODS: The study enrolled patients with malignant lung tumours who underwent transbronchial RFA using an automatic saline microperfusion system between January 2021 and December 2021 across 16 medical centres. The primary endpoint was the complete ablation rate. The performance and safety of the technique, along with the 1-year survival rates, were evaluated. RESULTS: This study included 126 patients (age range: 23-85 years) with 130 lung tumours (mean size: 18.77 × 14.15 mm) who had undergone 153 transbronchial RFA sessions, with a technique success rate of 99.35% and an average ablation zone size of 32.47 mm. At the 12-month follow-up, the complete ablation rate and intrapulmonary progression-free survival rates were 90.48% and 88.89%, respectively. The results of patients with ground-glass nodules (GGNs) were superior to those of the patients with solid nodules (12-month complete ablation rates: solid vs. pure GGN vs. mixed GGN: 82.14% vs. 100% vs. 96.08%, p = 0.007). No device defects were reported. Complications such as pneumothorax, haemoptysis, pleural effusion, pulmonary infection and pleural pain were observed in 3.97%, 6.35%, 8.73%, 11.11% and 10.32% of patients, respectively. Two subjects died during the follow-up period. CONCLUSION: Transbronchial RFA utilizing an automatic saline microperfusion system is a viable, safe and efficacious approach for the treatment for lung tumours, particularly for patients with GGNs.
引用
- Zhong C, Chen E, Su Z, et al. Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII). Respirology. 2024. PMID: 39197870. doi:10.1111/resp.14822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。